AP915A - Combination effective for the treatment of impotence. - Google Patents

Combination effective for the treatment of impotence. Download PDF

Info

Publication number
AP915A
AP915A APAP/P/1998/001414A AP9801414A AP915A AP 915 A AP915 A AP 915A AP 9801414 A AP9801414 A AP 9801414A AP 915 A AP915 A AP 915A
Authority
AP
ARIPO
Prior art keywords
alkyl
cgmp
composition
compound
treatment
Prior art date
Application number
APAP/P/1998/001414A
Other languages
English (en)
Other versions
AP9801414A0 (en
Inventor
Michael Grant Wyllie
Original Assignee
Pfizer Ireland Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22090927&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP915(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Ireland Pharmaceuticals filed Critical Pfizer Ireland Pharmaceuticals
Publication of AP9801414A0 publication Critical patent/AP9801414A0/xx
Application granted granted Critical
Publication of AP915A publication Critical patent/AP915A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
APAP/P/1998/001414A 1997-12-16 1998-12-10 Combination effective for the treatment of impotence. AP915A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6974197P 1997-12-16 1997-12-16

Publications (2)

Publication Number Publication Date
AP9801414A0 AP9801414A0 (en) 1998-12-31
AP915A true AP915A (en) 2000-12-18

Family

ID=22090927

Family Applications (1)

Application Number Title Priority Date Filing Date
APAP/P/1998/001414A AP915A (en) 1997-12-16 1998-12-10 Combination effective for the treatment of impotence.

Country Status (37)

Country Link
EP (1) EP1037616B1 (fr)
JP (2) JP2002508315A (fr)
KR (1) KR20010033092A (fr)
CN (1) CN1282248A (fr)
AP (1) AP915A (fr)
AR (1) AR016433A1 (fr)
AT (1) ATE318602T1 (fr)
AU (1) AU759825B2 (fr)
BG (1) BG104528A (fr)
BR (1) BR9813699A (fr)
CA (1) CA2314993A1 (fr)
CO (1) CO4810381A1 (fr)
CZ (1) CZ20002199A3 (fr)
DE (1) DE69833671T2 (fr)
DZ (1) DZ2675A1 (fr)
EA (1) EA200000526A1 (fr)
ES (1) ES2258300T3 (fr)
GT (1) GT199800177A (fr)
HN (1) HN1998000174A (fr)
HR (1) HRP20000407A2 (fr)
HU (1) HUP0100705A3 (fr)
IL (1) IL136515A0 (fr)
IS (1) IS5504A (fr)
MA (1) MA26586A1 (fr)
NO (1) NO20003065L (fr)
NZ (1) NZ504487A (fr)
OA (1) OA11423A (fr)
PA (1) PA8462801A1 (fr)
PE (1) PE20000011A1 (fr)
PL (1) PL341575A1 (fr)
SK (1) SK8782000A3 (fr)
TN (1) TNSN98227A1 (fr)
TR (1) TR200001733T2 (fr)
UY (1) UY25300A1 (fr)
WO (1) WO1999030697A2 (fr)
YU (1) YU33700A (fr)
ZA (1) ZA9811507B (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6469065B1 (en) 1996-02-02 2002-10-22 Nitromed, Inc. Nitrosated and nitrosylated α-adrenergic receptor antagonist, compositions and methods of use
US6331543B1 (en) 1996-11-01 2001-12-18 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use
DE19844162A1 (de) * 1998-09-25 2000-03-30 Udo Dunzendorfer Medikamentenkombinationen zur Therapie der erektilen Dysfunktion
WO2000053148A2 (fr) * 1999-03-08 2000-09-14 Merck & Co., Inc. Procedes et compositions pour le traitement de la dyserection
US7235625B2 (en) * 1999-06-29 2007-06-26 Palatin Technologies, Inc. Multiple agent therapy for sexual dysfunction
KR100738861B1 (ko) * 1999-08-03 2007-07-16 릴리 아이코스 엘엘씨 베타-카르볼린 약학 조성물
TWI265925B (en) 1999-10-11 2006-11-11 Pfizer Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them
WO2002022127A1 (fr) * 2000-09-13 2002-03-21 Isis Innovation Limited Utilisation d"inhibiteurs de phosphodiesterase pour le traitement de trouble ano-rectal
EP1333824B1 (fr) * 2000-11-17 2005-09-07 Warner-Lambert Company LLC Traitement de dysfonctionnements sexuels avec des antagonistes du recepteur de la bombesine
US20030114469A1 (en) * 2001-09-27 2003-06-19 Cohen David Saul Combinations
GB0219961D0 (en) 2002-08-28 2002-10-02 Pfizer Ltd Oxytocin inhibitors
GB0225908D0 (en) * 2002-11-06 2002-12-11 Pfizer Ltd Treatment of female sexual dysfunction
US7323462B2 (en) 2002-12-10 2008-01-29 Pfizer Inc. Morpholine dopamine agonists
CA2451267A1 (fr) 2002-12-13 2004-06-13 Warner-Lambert Company Llc Utilisations pharmaceutiques de ligands alpha2delta
US7291640B2 (en) 2003-09-22 2007-11-06 Pfizer Inc. Substituted triazole derivatives as oxytocin antagonists
AP2007004047A0 (en) 2005-01-20 2007-06-30 Pfizer Ltd Substituted triazole derivatives as oxtocin antagonists
US8506934B2 (en) 2005-04-29 2013-08-13 Robert I. Henkin Methods for detection of biological substances
BRPI0618643A2 (pt) 2005-11-09 2011-09-06 Combinatorx Inc composição compreendendo um par de fármacos, composição compreendendo um corticosteróide e um imunossupressor dependente de imunofilina não-esteróide, kits e uso
US8293489B2 (en) 2007-01-31 2012-10-23 Henkin Robert I Methods for detection of biological substances
US8580801B2 (en) 2008-07-23 2013-11-12 Robert I. Henkin Phosphodiesterase inhibitor treatment
CN101781302B (zh) * 2009-05-31 2013-07-10 段波 一种磷酸二酯酶抑制剂和异黄酮形成的加成物及其应用
EP2804603A1 (fr) 2012-01-10 2014-11-26 President and Fellows of Harvard College Composés promoteurs de réplication des cellules bêta et leurs procédés d'utilisation
WO2014055801A1 (fr) 2012-10-05 2014-04-10 Henkin Robert I Inhibiteurs de la phosphodiestérase destinés à traiter des troubles du goût et de l'odorat
US10598672B2 (en) 2014-02-18 2020-03-24 Cyrano Therapeutics, Inc. Methods and compositions for diagnosing and treating loss and/or distortion of taste or smell

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0459666A2 (fr) * 1990-05-31 1991-12-04 Pfizer Inc. Médicament contre l'impuissance
WO1994028902A1 (fr) * 1993-06-09 1994-12-22 Pfizer Limited Pyrazolopyrimidinones utilisees pour traiter l'impuissance

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA878182B (en) * 1986-11-05 1988-05-02 Merrell Dow Pharmaceuticals Inc. Enhancement of prazosin
FR2649613B1 (fr) * 1989-07-11 1991-09-27 Virag Ronald Medicament vaso-actif
US5242391A (en) * 1990-04-25 1993-09-07 Alza Corporation Urethral insert for treatment of erectile dysfunction
GB9523752D0 (en) * 1995-11-21 1996-01-24 Pfizer Ltd Pharmaceutical formulations

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0459666A2 (fr) * 1990-05-31 1991-12-04 Pfizer Inc. Médicament contre l'impuissance
WO1994028902A1 (fr) * 1993-06-09 1994-12-22 Pfizer Limited Pyrazolopyrimidinones utilisees pour traiter l'impuissance

Also Published As

Publication number Publication date
DE69833671T2 (de) 2006-11-30
ATE318602T1 (de) 2006-03-15
ES2258300T3 (es) 2006-08-16
OA11423A (en) 2004-04-21
NZ504487A (en) 2002-11-26
EP1037616B1 (fr) 2006-03-01
HN1998000174A (es) 1999-01-08
IS5504A (is) 2000-05-19
SK8782000A3 (en) 2002-03-05
CZ20002199A3 (cs) 2001-10-17
AP9801414A0 (en) 1998-12-31
GT199800177A (es) 2000-05-02
PA8462801A1 (es) 2000-05-24
DE69833671D1 (de) 2006-04-27
MA26586A1 (fr) 2004-12-20
JP2002508315A (ja) 2002-03-19
KR20010033092A (ko) 2001-04-25
CN1282248A (zh) 2001-01-31
PE20000011A1 (es) 2000-01-18
AU759825B2 (en) 2003-05-01
HUP0100705A2 (hu) 2001-08-28
NO20003065D0 (no) 2000-06-15
CA2314993A1 (fr) 1999-06-24
TR200001733T2 (tr) 2000-11-21
EA200000526A1 (ru) 2000-12-25
HUP0100705A3 (en) 2001-12-28
PL341575A1 (en) 2001-04-23
BR9813699A (pt) 2000-10-10
BG104528A (en) 2001-02-28
WO1999030697A2 (fr) 1999-06-24
AU9455898A (en) 1999-07-05
JP2007332156A (ja) 2007-12-27
DZ2675A1 (fr) 2003-03-29
EP1037616A2 (fr) 2000-09-27
UY25300A1 (es) 2000-12-29
IL136515A0 (en) 2001-06-14
ZA9811507B (en) 2000-06-19
AR016433A1 (es) 2001-07-04
HRP20000407A2 (en) 2000-10-31
TNSN98227A1 (fr) 2005-03-15
CO4810381A1 (es) 1999-06-30
YU33700A (sh) 2004-05-12
WO1999030697A3 (fr) 1999-08-26
NO20003065L (no) 2000-08-15

Similar Documents

Publication Publication Date Title
AP915A (en) Combination effective for the treatment of impotence.
US6127363A (en) Local administration of Type IV phosphodiesterase inhibitors for the treatment of erectile dysfunction
JP6247249B2 (ja) 眼障害のためのｐｄｅ１阻害剤
US6156753A (en) Local administration of type III phosphodiesterase inhibitors for the treatment of erectile dysfunction
EP1020190A2 (fr) Traitement de l' hyperplasie prostatique benigne avec des élévateurs du cGMP
US6476037B1 (en) L-arginine and phosphodiesterase (PDE) inhibitor synergism
US6436944B1 (en) Combination effective for the treatment of impotence
US20020004498A1 (en) Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
US20040063719A1 (en) Combination therapy using antihypertensive agents and endothelin antagonists
WO1999021558A2 (fr) Apport local d'inhibiteurs de phosphodiesterases, dans le traitement du dysfonctionnement erectile
AU749703B2 (en) Combination therapy for modulating the human sexual response
US20060142282A1 (en) Combination effective for the treatment of impotence
US7754767B2 (en) Method for treatment of premature ejaculation in humans
EP1676573A1 (fr) Composition pharmaceutique comprenant un composé 2,5-dihydroxybenzensulfonique, un modulateur des canaux de potassium et un inhibiteur de la phosphodiesterase 5
US20100311785A1 (en) Combination Therapy For Modulating The Human Sexual Response
Snow Erectile dysfunction: a review and update
JP2002249446A (ja) 不能の治療に効果的な多剤併用薬
MXPA00009614A (en) Combination effective for the treatment of impotence comprising a potassium-channel-opener and a cgmp elevator
MXPA99010400A (en) Combination therapy for modulating the human sexual response